Detalhe da pesquisa
1.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 385(12): 1091-1103, 2021 09 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34161051
2.
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Prostate
; 79(14): 1683-1691, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31442327
3.
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Cancer
; 125(23): 4172-4180, 2019 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31483485
4.
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
Cancer
; 126(12): 2935-2937, 2020 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32154908
5.
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
Eur Urol
; 2024 Apr 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38644146
6.
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Eur Urol
; 83(1): 15-26, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36055895
7.
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 24(21): 5225-5232, 2018 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30012563
8.
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer
; 16(2): 149-154, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29196208
9.
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].
Eur Urol
; 83(3): e87, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-36528479
10.
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 22(6): 1356-63, 2016 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26527750
11.
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Clin Genitourin Cancer
; 13(3): e191-8, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25557266
12.
DNA vaccines: an active immunization strategy for prostate cancer.
Semin Oncol
; 30(5): 659-66, 2003 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-14571413
13.
Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung.
Chest
; 126(2): 347-51, 2004 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-15302716
14.
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
J Clin Oncol
; 29(16): 2191-8, 2011 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-21483004
15.
Octreotide for gastrointestinal bleeding of obscure origin in an anticoagulated patient.
Dig Dis Sci
; 47(7): 1514-5, 2002 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-12141810